Literature DB >> 12063468

Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.

W Roy Smythe1, Imran Mohuiddin, Mustafa Ozveran, Xiaobo X Cao.   

Abstract

OBJECTIVE: Malignant pleural mesothelioma is resistant to conventional therapies and to apoptosis. The bcl-2 family genes are major determinants of apoptotic homeostasis. Malignant pleural mesothelioma lines and tumors rarely express the antiapoptotic Bcl-2 protein but routinely express the antiapoptotic protein Bcl-xl and the proapoptotic proteins Bax and Bak. We have previously shown pharmacologic inhibition of bcl-xl expression in malignant pleural mesothelioma can lead to apoptosis, so we sought to determine whether antisense oligonucleotides directed at bcl-xl messenger RNA would engender apoptosis, possibly through a "forced imbalance" of bcl-2 family proteins.
METHODS: Malignant pleural mesothelioma lines REN (epithelial) and I-45 (sarcomatous) were exposed to modified bcl-xl antissense oligonecleotides directed near the messenger RNA initiation sequence with and without a liposomal delivery system. Untreated cells and bcl-xl sense oligonucleotides were controls. Cell viability was measured by colorimetric assay, and apoptosis was evaluated with Hoechst staining and sub-G(1) fluorescence-activated cell sorter analysis.
RESULTS: Bcl-xl protein expression after antisense oligonucleotides was downwardly regulated in both cell lines relative to sense oligonucleotides (>65%). Significant cellular killing in both the I-45 and REN cell lines was achieved with antisense oligonucleotides (compared with sense oligonucleotides) without (P =.003 and.006, respectively) and with (P =.006 and.0005, respectively) liposomal delivery. Hoechst staining and sub-G(1) fluorescence-activated cell sorter analysis demonstrated apoptosis to be the mechanism of cellular death. Use of a liposomal delivery system increased therapeutic effect and allowed lower doses of antisense oligonucleotides.
CONCLUSION: Antisense oligonucleotides directed at the bcl-xl gene product engender apoptosis in mesothelioma cell lines. The therapeutic potential of inhibiting expression of this protein in mesothelioma should be evaluated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063468     DOI: 10.1067/mtc.2002.121684

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors.

Authors:  Xiaobo Cao; James Littlejohn; Charles Rodarte; Lidong Zhang; Benjamin Martino; Philip Rascoe; Kamran Hamid; Daniel Jupiter; W Roy Smythe
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

2.  Relevance of Bcl-x expression in different types of endometrial tissues.

Authors:  Xiaoxin Ma; Yanhui Zhao; Yanxia Li; Hongwei Lu; Yuanqi He
Journal:  J Exp Clin Cancer Res       Date:  2010-02-23

3.  Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.

Authors:  Sharyn I Katz; Lanlan Zhou; Grace Chao; Charles D Smith; Thomas Ferrara; Wenge Wang; David T Dicker; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2009-12-02       Impact factor: 4.742

Review 4.  Current therapy for malignant mesothelioma.

Authors:  W Roy Smythe
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.945

5.  BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.

Authors:  Surein Arulananda; Megan O'Brien; Marco Evangelista; Tiffany J Harris; Nikita S Steinohrt; Laura J Jenkins; Marzena Walkiewicz; Robert J J O'Donoghue; Ashleigh R Poh; Bibhusal Thapa; David S Williams; Trishe Leong; John M Mariadason; Xia Li; Jonathan Cebon; Erinna F Lee; Thomas John; W D Fairlie
Journal:  Cell Death Discov       Date:  2020-10-31

6.  Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.

Authors:  Marco Tomasetti; Lory Santarelli
Journal:  Cancers (Basel)       Date:  2010-04-14       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.